Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: Relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo

Biochemical Pharmacology

Volumn 62, Issue 10, 2001, Pages 1371-1377

  Phillips, Roger M ^a   Burger, Angelika M ^b   Fiebig, Heinz Herbert ^b   Double, John A ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Mitomycin C; NQO1; Pharmacogenetics; Polymorphism; Xenografts

Indexed keywords

MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR CLASSIFICATION; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; FMN REDUCTASE; GENOTYPE; HUMANS; MICE; MICE, NUDE; MITOMYCIN; NADH, NADPH OXIDOREDUCTASES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; POLYMORPHISM, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035892352     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00769-9     Document Type: Article

References (27)

1. A critical appraisal of the predictive value of in vitro chemosensitivity assays
2. Pharmacogenetics and the practice of medicine
3. Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase
4. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumor xenografts to mitomycin C
5. NAD(P)H:Quinone oxidoreductase gene expression in human colon carcinoma cells: Characterisation of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
6. Characterisation of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase)
7. NAD(P)H:quinone oxidoreductase: Polymorphism and allele frequency in Caucasian, Chinese and Canadian native Indian and Inuit populations
8. Metabolism of MMC by DT-diaphorase: Role in MMC induced DNA damage and cytotoxicity in human colon carcinoma cells
9. Loss of heterozygosity at the NAD(P)H:Quinone oxidoreductase locus associated with increased resistance against MMC in a human bladder carcinoma cell line
10. Clinical significance of NAD(P)H:quinone oxidoreductase 1 C609T polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal MMC
11. Genetic polymorphism of NAD(P)H:Quinone oxidoreductase and MMC sensitivity in gastric cancer
12. Enzymology of MMC metabolic activation in tumor tissue. Implications for enzyme directed bioreductive drug development
13. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme directed bioreductive drug development
14. Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumors
15. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1
16. Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity
17. Combined in vivo/in vivo test procedure with human tumour xenografts
18. Transgenic expression of human MGMT protects against azoxymethane induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon
19. United Kingdom Co-ordinating committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. 2nd ed
20. Unusually marked hypoxic sensitisation to indoloquinone EO9 and Mitomycin C in a human colon carcinoma cell line which lacks DT-diaphorase
21. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells over expressing human NADPH:cytochrome c (P450) reductase
22. Establishment of an isogenic human colon tumour model for NQO1 gene expression: Application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo
23. Expression of human NAD(P)H:Quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: Effect on the toxicity of antitumour quinones
24. The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase?
25. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9
26. A new screening system for NAD(P)H: Quinone oxidoreductase (NQO1) directed antitumour quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1 directed antitumor agent
27. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino 17-demethoxygeldanomycin, an inhibitor of heat shock protein 90